Abstract
CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea. Though neutropenia is manageable, CPT-11 induced diarrhea is frequently severe, resulting in hospitalizations, dose reductions or omissions leading to ineffective treatment administration. Many potential agents have been tested in preclinical and clinical studies to prevent or ameliorate CPT-11 induced late onset diarrhea. It is predicted that prophylaxis of CPT-11 induced diarrhea will reduce sub-therapeutic dosing as well as hospitalizations and will eventually lead to dose escalations resulting in better response rates. This article reviews various experimental agents and strategies employed to prevent this debilitating toxicity. Covered topics include schedule/dose modification, intestinal alkalization, structural/chemical modification, genetic testing, anti-diarrheal therapies, transporter (ABCB1, ABCC2, BCRP2) inhibitors, enzyme (β-glucuronidase, UGT1A1, CYP3A4, carboxylesterase, COX-2) inducers and inhibitors, probiotics, antibiotics, adsorbing agents, cytokine and growth factor activators and inhibitors and other miscellaneous agents.
Keywords: Chemotherapy induced diarrhea, CPT-11 (irinotecan), diarrhea prevention and control, CPT-11 metabolism, toxicity, antidiarrheals/pharmacology, enzyme inhibitors/pharmacology.
Current Drug Targets
Title:Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Volume: 14 Issue: 7
Author(s): Umang Swami, Sanjay Goel and Sridhar Mani
Affiliation:
Keywords: Chemotherapy induced diarrhea, CPT-11 (irinotecan), diarrhea prevention and control, CPT-11 metabolism, toxicity, antidiarrheals/pharmacology, enzyme inhibitors/pharmacology.
Abstract: CPT-11 (irinotecan), a DNA topoisomerase I inhibitor is one of the main treatments for colorectal cancer. The main dose limiting toxicities are neutropenia and late onset diarrhea. Though neutropenia is manageable, CPT-11 induced diarrhea is frequently severe, resulting in hospitalizations, dose reductions or omissions leading to ineffective treatment administration. Many potential agents have been tested in preclinical and clinical studies to prevent or ameliorate CPT-11 induced late onset diarrhea. It is predicted that prophylaxis of CPT-11 induced diarrhea will reduce sub-therapeutic dosing as well as hospitalizations and will eventually lead to dose escalations resulting in better response rates. This article reviews various experimental agents and strategies employed to prevent this debilitating toxicity. Covered topics include schedule/dose modification, intestinal alkalization, structural/chemical modification, genetic testing, anti-diarrheal therapies, transporter (ABCB1, ABCC2, BCRP2) inhibitors, enzyme (β-glucuronidase, UGT1A1, CYP3A4, carboxylesterase, COX-2) inducers and inhibitors, probiotics, antibiotics, adsorbing agents, cytokine and growth factor activators and inhibitors and other miscellaneous agents.
Export Options
About this article
Cite this article as:
Swami Umang, Goel Sanjay and Mani Sridhar, Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070007
DOI https://dx.doi.org/10.2174/1389450111314070007 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Nanostructured Silica-Lipid Hybrid to Facilitate Oral SN-38-based Chemotherapy
Drug Delivery Letters Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets VEGFA and PlGF Protein Signature of Primary Stage IV Rectal Cancer Pre and Post Neoadjuvant Radiotherapy, Bevacizumab, and Chemotherapy
Current Angiogenesis (Discontinued) Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology Molecular Markers for Individualized Therapy in Colorectal Cancer: Progress Towards a Pharmacogenomics Array
Current Pharmacogenomics and Personalized Medicine Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry Synthesis of New Curcumin-like Pentadienones by O- and C-glycosylation
Current Organic Chemistry Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP
Current Cancer Drug Targets The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science The Immunomodulation and Anti-Inflammatory Effects of Garlic Organosulfur Compounds in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of the Histamine H4 Receptor in Anti-inflammatory Therapy
Current Topics in Medicinal Chemistry Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry EGFR Expression Correlates with Maximum Standardized Uptake Value of 18F- fluorodeoxyglucose-PET in Squamous Cell Lung Carcinoma
Current Radiopharmaceuticals Editorial [Clinical Applications of Advanced CT, MRI and Optical Imagings as Well as Spect]
Current Medical Imaging